VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2023 | PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC

Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, presents findings from the Phase III PARADIGM trial (NCT02394795) of panitumumab versus bevacizumab in patients with RAS wild-type, left-sided metastatic colorectal cancer (mCRC). Patients received modified-FOLFOX6 with panitumumab or bevacizumab, where overall survival was the primary endpoint. Negative hyperselection using ctDNA rather than tumor sidedness may identify patients who will benefit from panitumumab more efficiently. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter